Clinical Trials on Blood Coagulation Tests ( INR, APTT) in New Zealand

Total 524 results

Accriva Diagnostics

Unknown

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

Blood Coagulation Test

United States
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Hemophilia A

United States, New Zealand, Australia, Hungary, Sweden, Austria, Poland, Romania
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Lumen Biomedical

Completed

Xtract™ Aspiration Catheter Registry Study

Fresh Soft Emboli or Thrombi in the Arteries.

New Zealand
Baxalta now part of Shire

Completed

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Hemophilia A | Hemophilia B | Hemophilia A or B With Inhibitors

Poland, United States, Bulgaria, Romania, Japan, Russian Federation, New Zealand, Croatia, Ukraine, Brazil
Stony Brook University

Completed

Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

Coagulation Disorder

United States
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Stony Brook University

Completed

The Acute Effects of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers

Coagulation Disorder

United States
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Mary M. Gooley Hemophilia Center

Completed

The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders

Hemophilia | vonWillebrand Disease | Platelet Coagulation Disorders

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Green Cross Corporation
Atlantic Research Group

Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Hemophilia A

United States
Weill Medical College of Cornell University

Withdrawn

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Von Willebrand Disease

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
University of Rochester

Terminated

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

Blood Coagulation Disorder

United States
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Completed

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia (IG0902)

Congenital Afibrinogenemia

India, United States, Italy, Lebanon
Healthcare Innovation Technology Lab
Bayer

Unknown

Hemophilia Mobile App Usability Pilot

Hemophilia

United States
Montefiore Medical Center
Genentech, Inc.

Not yet recruiting

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

Hemophilia A

United States
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...
Sintesi Research Srl

Unknown

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients (ITI)

Hemophilia A

India, Egypt
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of ADVATE in People With Hemophilia A in India

Hemophilia A

India
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
CSL Behring

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (IX-TEND 4001)

Hemophilia B

United States
Tulane University
Genentech, Inc.

Recruiting

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Hemophilia A

United States
Pfizer

Completed

Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters. (MOSAIC)

Blood Coagulation

United States
Pfizer

Completed

A Gene Therapy Study for Hemophilia B

Hemophilia B

United States, Australia
Octapharma

Completed

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Germany, Bulgaria
Baxalta now part of Shire

Completed

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States
Genentech, Inc.

Terminated

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Hemophilia A

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating rFIX; BeneFIX in Severe Hemophilia B

Hemophilia B

United States
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

Hemophilia A

United States
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
University of California, Davis

Terminated

INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)

Hemophilia A | Hemophilia A With Inhibitor

United States
Bayer
American Thrombosis and Hemostasis Network

Terminated

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Hemophilia A

United States
Tulane University School of Medicine

Completed

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors (ProFEIBA)

Hemophilia A With Inhibitors

United States
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Instituto Grifols, S.A.

Withdrawn

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis

Hypofibrinogenemia | Congenital Afibrinogenemia

India, Turkey, Lebanon, United States, Bulgaria
Bayer

Completed

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Hemophilia A

Belgium, New Zealand, Netherlands, Greece, United Kingdom, Austria, United States, Italy, Romania, Bulgaria, Canada, Israel, Poland, Lithuania, Norway, Argentina, Spain
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
Bayer

Terminated

A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers (REAL)

Hemophilia A

United States
Bio Products Laboratory

Completed

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

Factor 10 Deficiency

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa

Clinical Trials on Blood Coagulation Tests ( INR, APTT) in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations